trial

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

NCTId NCT00644969
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 128 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2010-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
128 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-05
Primary completion
2010-04
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
varenicline (CP-526,555)

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

14 total
Aurora, United StatesFarmington, United StatesNew Haven, United StatesWorcester, United StatesNew Brunswick, United StatesDurham, United StatesCincinnati, United StatesPittsburgh, United StatesHouston, United StatesEdmonton, CanadaMississauga, CanadaToronto, Canada

Linked catalysts

1
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disor — primary completion2010-04

Facts & assertions

4 sourced
Enrollment
128
Phase
PHASE3
Primary Completion Date
2010-04
Status
COMPLETED
relationships
The graph out of here
drug
varenicline (CP-526,555)
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Smoking Cessation
indication
Smoking Cessation
indication